CADTH | Evidence Driven
CADTH | Evidence Driven

NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness

Details

Files
Project Status:
Completed
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA0989-000

Question


  1. What is the clinical effectiveness of NY-ESO T-cell immunotherapy in adults with recurrent or refractory ovarian cancer?


Key Message

No relevant literature was identified regarding the clinical effectiveness of NY-ESO T-cell immunotherapy in adults with recurrent or refractory ovarian cancer.


Files

NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness Rapid Response November 15, 2018 View PDF

Related Content

Last Updated : November 15, 2018